Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Affimed, Roche Explore AFM24, Tecentriq Combo | Contract Pharma

What are you searching for?

Sign in
Breaking News

Affimed, Roche Explore AFM24, Tecentriq Combo

To investigate the combination for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
 
Affimed will fund and conduct a Phase 1/2a trial to investigate the combination of AFM24 and atezolizumab for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies in patients whose disease has progressed after treatment with previous anticancer therapies. Roche will supply Affimed with atezolizumab for the clinical trial. The Phase 1/2a study will establish a dosing regimen for the combination therapy and assess safety and potential activity.
 
AFM24 is a novel tetravalent, bispecific EGFR- and CD16A-binding innate cell engager that activates innate immunity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). AFM24 is currently being evaluated as monotherapy in adult patients with advanced solid malignancies known to be EGFR-positive in an open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics